
    
      Primary Objective:

      To determine whether a single dose of zoledronic acid pre-transplant will prevent
      HSCT-related bone loss without impeding engraftment, compared with placebo.

      Secondary Objectives:

      To identify bone and muscle deficits and alterations in fat distribution prior to HSCT,
      compared with healthy controls.
    
  